A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML

Wenxin Du; Zhimei Xia; Zebin Luo; Yichang Chen; Shaowei Bing; Wei Wang; Xingya Zhang; Zhan Zhou; Jingying Zhang; Ji Cao; Bo Yang; Qiaojun He; Xuejing Shao; Xiaojun Xu; Meidan Ying

doi:10.1038/s41375-023-02024-6

A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML

Leukemia. 2023 Nov;37(11):2286-2291. doi: 10.1038/s41375-023-02024-6. Epub 2023 Sep 15.

Authors

Wenxin Du¹, Zhimei Xia¹, Zebin Luo², Yichang Chen³, Shaowei Bing¹, Wei Wang¹, Xingya Zhang¹, Zhan Zhou³, Jingying Zhang², Ji Cao^{1

4}, Bo Yang^{1

4}, Qiaojun He^{1

4

5}, Xuejing Shao⁶, Xiaojun Xu⁷, Meidan Ying^{8

9

10

11}

Affiliations

¹ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China.
² Division of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China.
³ Innovation Institute for Artificial Intelligence in Medicine, Zhejiang Provincial Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences and Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Zhejiang University, 310018, Hangzhou, China.
⁴ Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, 310000, Hangzhou, China.
⁵ Cancer Center, Zhejiang University, 310058, Hangzhou, China.
⁶ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China. xjshao@zju.edu.cn.
⁷ Division of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China. xuxiaojun@zju.edu.cn.
⁸ Institute of Pharmacology and Toxicology, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, China. mying@zju.edu.cn.
⁹ Division of Hematology-Oncology, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, 310052, Hangzhou, China. mying@zju.edu.cn.
¹⁰ Engineering Research Center of Innovative Anticancer Drugs, Ministry of Education, 310000, Hangzhou, China. mying@zju.edu.cn.
¹¹ Cancer Center, Zhejiang University, 310058, Hangzhou, China. mying@zju.edu.cn.

PMID: 37714925
DOI: 10.1038/s41375-023-02024-6

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't
Letter

MeSH terms

Core Binding Factor Alpha 2 Subunit* / genetics
Gene Expression Regulation, Leukemic
Gene Fusion
Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / genetics
Neoplasm Recurrence, Local / genetics
Nuclear Pore Complex Proteins / genetics
Oncogene Proteins, Fusion / genetics
Translocation, Genetic

Substances

Core Binding Factor Alpha 2 Subunit
nuclear pore complex protein 98
Nuclear Pore Complex Proteins
Oncogene Proteins, Fusion
RUNX1 protein, human

Grants and funding

82273942/National Natural Science Foundation of China (National Science Foundation of China)